Background: Intermittent theta-burst stimulation (iTBS) is an FDA-approved treatment for treatment-resistant
depression (TRD). Typical courses involve daily stimulation sessions for six weeks
and average response rates are around 50%. Several studies have demonstrated the safety
and potential enhanced efficacy of accelerated theta-burst stimulation. Higher pre-treatment
anti-correlation between the stimulated region of the left dorsolateral prefrontal
cortex (L-DLPFC) and subcallosal cingulate cortex (SCC) has been associated with better
To read this article in full you will need to make a payment
© 2018 Published by Elsevier Inc.